This open-label Phase II trial (n=30) evaluated the safety and efficacy of psilocybin for anxiety depression.
It has been shown that different psychological factors may influence a person’s response to treatment. For example, studies have shown that people with certain character traits, beliefs, thought processes etc may be more likely to respond to certain therapy or treatment more than others. Psilocybin has been shown to result in temporary changes in these mental processes that may create a change in the way a person receives and processes new information – such as psychological therapy. In this study, all participants will receive psilocybin within two to four weeks after completion of therapy, and then changes in mood and cognition will be followed-up.